KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Receivables (2023 - 2025)

Biocryst Pharmaceuticals' Change in Receivables history spans 9 years, with the latest figure at $15.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 112.36% year-over-year to $15.5 million; the TTM value through Dec 2025 reached $36.8 million, up 62.16%, while the annual FY2025 figure was $36.8 million, 62.16% up from the prior year.
  • Change in Receivables reached $15.5 million in Q4 2025 per BCRX's latest filing, up from $17000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $15.5 million in Q4 2025 to a low of -$3.8 million in Q3 2023.
  • Average Change in Receivables over 3 years is $5.5 million, with a median of $5.6 million recorded in 2024.
  • Peak YoY movement for Change in Receivables: skyrocketed 290.14% in 2024, then crashed 99.49% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $3.0 million in 2023, then surged by 145.66% to $7.3 million in 2024, then surged by 112.36% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Change in Receivables are $15.5 million (Q4 2025), $17000.0 (Q3 2025), and $7.3 million (Q2 2025).